LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma
LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma
Recruiting · NCT07100067 · Registry updated 2025-12-29Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Not applicable | 2025-12-29 | NCT07100067 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Institute of Hematology & Blood Diseases Hospital, China | 285 |
| Nanjing Legend Biotech Co. | 13 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Beijing Boren Hospital | Beijing | China | 3 |
| Institute of Hematology & Blood Diseases Hospital | Tianjin | China | 12 |
| Wuhan Union Hospital | Wuhan | China | 4 |